四環醫藥(00460.HK):抗血栓藥替格瑞洛片(60毫克及90毫克)獲藥品註冊批件
格隆匯1月10日丨四環醫藥(00460.HK)發佈公吿,集團開發的抗血栓藥替格瑞洛片(60毫克及90毫克)已獲中國國家藥品監督管理局頒發的藥品註冊批件,視同通過仿製藥質量和療效一致性評價。
根據披露,替格瑞洛是一種新型抗血栓藥,用於急性冠脈綜合症(ACS)患者或有心肌梗死病史且伴有至少一種動脈粥樣硬化血栓形成事件高危因素的患者,降低心血管死亡、心肌梗死和卒中的發生率。替格瑞洛無需經過肝臟代謝活化,具有快速、強效的特點,受到多個國內外治療指南的推薦,極具市場潛力。替格瑞洛片為中國國家醫保乙類(2021年)藥。
據IQVIA數據,2017至2020年,替格瑞洛中國國內銷售額逐年增加,分別為人民幣4.2、8.7、16.1、17.8億元,年複合增長率為61.46%;在抗血小板凝聚抑制劑藥物領域市場規模位居前三,市佔比逐年增加,由2017年的3%增長至2020年的20%。抗血栓領域為集團重點佈局領域,本次該產品獲頒《藥品註冊證書》,將進一步惠及廣大患者,同時為集團的抗血栓藥物管線再添一重磅品種,利於該藥品未來的市場銷售和市場競爭,對集團的經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.